Validation experiment designed to validate causal mechanisms targeting C1q in LPS-treated mice with C1q antibody intervention. Primary outcome: rescue of behavioral deficits, reduced synaptic loss, decreased abnormal microglial phagocytosis
This therapeutic intervention experiment involved treating LPS-induced depressed mice with a C1q neutralizing antibody to test whether inhibiting the C1q/C3-CR3 signaling pathway could rescue the behavioral and synaptic deficits. The study examined whether blocking C1q could reduce abnormal microglial phagocytosis of synapses, prevent synaptic loss, and improve depressive and anxiety-like behaviors in the mouse model. This experiment was crucial for establishing the causal relationship between the complement pathway and the observed pathological changes. The researchers assessed the same parameters as in the first experiment but now with the addition of the therapeutic intervention to determine if pathway inhibition could reverse the LPS-induced effects on behavior, synaptic integrity, and microglial function.
LPS-induced depression model followed by C1q neutralizing antibody treatment, with subsequent assessment of behaviors, synaptic markers, microglial phagocytosis, and complement pathway activity
C1q antibody treatment would reduce microglial phagocytosis, preserve synapses, and improve behavioral outcomes
significant improvement in behavioral measures, reduced synaptic loss, and decreased abnormal microglial activity compared to LPS-only treated mice
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.